Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Mydecine Innovations Group Inc (MYCOF) Message Board

Captivating Documentary Explores Psychedelics’ R

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 160
(Total Views: 379)
Posted On: 11/16/2021 5:36:19 PM
Avatar
Posted By: NetworkNewsWire
Captivating Documentary Explores Psychedelics’ Role in PTSD Treatment

The focus on mental health has been growing as more research on psychedelic substances and their potential benefits as alternative treatments of various mental health conditions is conducted. Thus far, research has found that psychedelics such as mescaline, LSD and psilocybin mushrooms can help treat mental conditions, including depression, anxiety, addiction and post-traumatic stress disorder.

Attention on this space has also been emphasized by the numerous literary works on the substances that are being published. A new documentary film on psychedelics, titled “Breaking Through,” which was directed and produced by Dan Laughton, a filmmaker based in London, is one of these works. Laughton is a graduate of Ravensbourne University. He’s been building his career by working with various major brands, which include LADbible, the British Army and Reebok.

Laughton’s objective in the creation of documentaries is to produce raw stories that have a cinematic touch and people can resonate with. In an interview with Creative Boom, the director notes that while his work varies from commercial work to documentaries, he follows his passion of exploring different individuals, as well as their stories and what makes them tick. He asserted that his goal was to progress into longer documentaries, revealing that he had many projects and pitches at different stages of development.

The short documentary questions if policymakers were wrong to begin a war on psychedelics as well as investigating the role that psychedelic substances can play with regard to helping those suffering with post-traumatic stress disorder. Post-traumatic stress disorder is a mental health condition characterized by a failure to recover after witnessing or experiencing a terrifying event. The documentary centers on the story Guy Murray, an army veteran who served in the Afghanistan war.

It examines how sessions of psychedelic-assisted therapy assisted him in working through his trauma as well as his feelings of depression that he had sustained during his time in the war. It also looks into how we as a society treat mental health, noting that while the conversation on mental health has gained ground in the recent years, society still has a long way to go.

Currently, one in five individuals in the United Kingdom suffer from trauma, depression and anxiety. The UK is at the foreground of psychedelic-assisted therapy,as advocates and physicians continue to push for more treatments that can be incorporated into psychotherapy.

This film also shows how those who suffer from trauma are stuck in the middle of the decades-long drug war, which has left many experts wondering whether we would have more understanding of psychedelic substances and their use in therapy if the substances were better understood. The full documentary, which is 20 minutes long, can be viewed on Vimeo.

In case you are tempted to think that the contents of this documentary are heavily embellished in true Hollywood style, consider the fact that companies such as Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) are heavily invested in leveraging psychedelics in order to come up with superior medicines for mental health conditions.

NOTE TO INVESTORS: The latest news and updates relating to Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) are available in the company’s newsroom at https://ibn.fm/MYCOF

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer






(0)
(0)




Mydecine Innovations Group Inc (MYCOF) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us